Dyne Therapeutics’ (DYN) Buy Rating Reiterated at Chardan Capital

Chardan Capital restated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a research report released on Monday morning,Benzinga reports. They currently have a $50.00 target price on the stock.

Several other research firms have also recently weighed in on DYN. Piper Sandler lowered their target price on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Robert W. Baird started coverage on Dyne Therapeutics in a research note on Friday, December 13th. They issued an “outperform” rating and a $46.00 price target for the company. BMO Capital Markets started coverage on Dyne Therapeutics in a research note on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 price target for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $45.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. Finally, Raymond James raised Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $48.85.

Dyne Therapeutics Price Performance

NASDAQ:DYN opened at $12.40 on Monday. Dyne Therapeutics has a fifty-two week low of $11.18 and a fifty-two week high of $47.45. The stock’s 50-day moving average is $13.89 and its two-hundred day moving average is $24.58. The stock has a market cap of $1.40 billion, a PE ratio of -3.48 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.04. On average, equities research analysts anticipate that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the transaction, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 6,237 shares of company stock valued at $77,760 over the last 90 days. 20.77% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Quantbot Technologies LP acquired a new position in shares of Dyne Therapeutics in the third quarter valued at $34,000. Point72 DIFC Ltd acquired a new position in shares of Dyne Therapeutics in the third quarter valued at $36,000. US Bancorp DE raised its stake in shares of Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after purchasing an additional 1,212 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Dyne Therapeutics in the fourth quarter valued at $50,000. Finally, KBC Group NV raised its stake in shares of Dyne Therapeutics by 45.3% in the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after purchasing an additional 978 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.